Saikosaponin B2
CAS: 58316-41-9
Ref. TM-T3810
| 1mg | 42.00 € | ||
| 5mg | 85.00 € | ||
| 10mg | 133.00 € | ||
| 25mg | 234.00 € | ||
| 50mg | 352.00 € | ||
| 100mg | 527.00 € | ||
| 500mg | 1,147.00 € |
Estimated delivery in United States, on Monday 13 Jan 2025
Product Information
Name:
Saikosaponin B2
Synonyms:
- Saikosaponin B-2
- (3b,4a,16a)-16,23,28-Trihydroxyoleana-11,13(18)-dien-3-yl-6-deoxy-3-O-beta-D-glucopyranosyl-beta-D-galactopyranoside
- (3beta,16alpha)-16,23,28-trihydroxyoleana-11,13(18)-dien-3-yl 6-deoxy-3-O-beta-D-glucopyranosyl-beta-D-galactopyranoside
- (3β,4α,16α)-16,23,28-Trihydroxyoleana-11,13(18)-dien-3-yl 6-deoxy-3-O-β-<span class="text-smallcaps">D</smallcap>-glucopyranosyl-β-<smallcap>D</span>-galactopyranoside
- Saikosaponin B<sub>2</sub>
- β-<span class="text-smallcaps">D</smallcap>-Galactopyranoside, (3β,4α,16α)-16,23,28-trihydroxyoleana-11,13(18)-dien-3-yl 6-deoxy-3-O-β-<smallcap>D</span>-glucopyranosyl-
- (3β,4α,16α)-16,23,28-Trihydroxyoleana-11,13(18)-dien-3-yl 6-deoxy-3-O-β-D-glucopyranosyl-β-D-galactopyranoside
- β-D-Galactopyranoside, (3β,4α,16α)-16,23,28-trihydroxyoleana-11,13(18)-dien-3-yl 6-deoxy-3-O-β-D-glucopyranosyl-
Description:
Saikosaponin B2 inhibits HCV, blocks viral binding to hepatoma cells, and induces melanoma differentiation, enhancing tyrosinase and melanogenesis.
Notice:
Our products are intended for lab use only. For any other use, please contact us.
Brand:
Targetmol
Long term storage:
Notes:
Chemical properties
Molecular weight:
780.98
Formula:
C42H68O13
Purity:
99.59% - 99.88%
Color/Form:
Solid
MDL:
Melting point:
Boiling point:
Flash point:
Density:
Concentration:
EINECS:
Merck:
HS code:
Technical inquiry about: TM-T3810 Saikosaponin B2
Please use instead the cart to request a quotation or an order
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
